BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21623761)

  • 21. Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.
    Shi Y; Zhao X; Durkin L; Rogers HJ; Hsi ED
    Hum Pathol; 2016 Jun; 52():173-8. PubMed ID: 26980048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.
    Lin X; Zou X; Wang Z; Fang Q; Chen S; Huang J; Zhe N; Yu M; Zhang Y; Wang J
    Oncotarget; 2016 Aug; 7(33):53679-53701. PubMed ID: 27447561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphoma.
    Popov SW; Moldenhauer G; Wotschke B; Brüderlein S; Barth TF; Dorsch K; Ritz O; Möller P; Leithäuser F
    Cancer Res; 2007 Jul; 67(14):6555-64. PubMed ID: 17638864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation.
    Chiaretti S; Li X; Gentleman R; Vitale A; Wang KS; Mandelli F; Foà R; Ritz J
    Clin Cancer Res; 2005 Oct; 11(20):7209-19. PubMed ID: 16243790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linking miRNA regulation to BCR-ABL expression: the next dimension.
    Faber J; Gregory RI; Armstrong SA
    Cancer Cell; 2008 Jun; 13(6):467-9. PubMed ID: 18538729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
    Castor A; Nilsson L; Astrand-Grundström I; Buitenhuis M; Ramirez C; Anderson K; Strömbeck B; Garwicz S; Békássy AN; Schmiegelow K; Lausen B; Hokland P; Lehmann S; Juliusson G; Johansson B; Jacobsen SE
    Nat Med; 2005 Jun; 11(6):630-7. PubMed ID: 15908956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Usefulness of molecular screening in childhood lymphoblastic leukemias].
    Anguita E; González FA; Contra T; Martín N; Valverde F; Villegas A
    Sangre (Barc); 1998 Feb; 43(1):7-11. PubMed ID: 9577176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversibility of acute B-cell leukaemia induced by BCR-ABL1.
    Huettner CS; Zhang P; Van Etten RA; Tenen DG
    Nat Genet; 2000 Jan; 24(1):57-60. PubMed ID: 10615128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. E-proteins directly regulate expression of activation-induced deaminase in mature B cells.
    Sayegh CE; Quong MW; Agata Y; Murre C
    Nat Immunol; 2003 Jun; 4(6):586-93. PubMed ID: 12717431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia.
    Behrens K; Brajanovski N; Xu Z; Viney EM; DiRago L; Hediyeh-Zadeh S; Davis MJ; Pearson RB; Sanij E; Alexander WS; Ng AP
    Sci Adv; 2024 Mar; 10(10):eadj8803. PubMed ID: 38457494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
    Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
    Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Children and adults with acute lymphoblastic leukaemia have similar gene expression profiles.
    Kuchinskaya E; Heyman M; Grandér D; Linderholm M; Söderhäll S; Zaritskey A; Nordgren A; Porwit-Macdonald A; Zueva E; Pawitan Y; Corcoran M; Nordenskjöld M; Blennow E
    Eur J Haematol; 2005 Jun; 74(6):466-80. PubMed ID: 15876250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. γ-Catenin-Dependent Signals Maintain BCR-ABL1
    Luong-Gardiol N; Siddiqui I; Pizzitola I; Jeevan-Raj B; Charmoy M; Huang Y; Irmisch A; Curtet S; Angelov GS; Danilo M; Juilland M; Bornhauser B; Thome M; Hantschel O; Chalandon Y; Cazzaniga G; Bourquin JP; Huelsken J; Held W
    Cancer Cell; 2019 Apr; 35(4):649-663.e10. PubMed ID: 30991025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
    Rudolph C; Hegazy AN; von Neuhoff N; Steinemann D; Schröck E; Stripecke R; Klein C; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Aug; 161(1):51-6. PubMed ID: 16080957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
    Gestrich CK; De Lancy SJ; Kresak A; Meyerson H; Pateva I; Yalley AK; Ryder C; Shetty S; Bledsoe J; Moore EM; Oduro KA
    Br J Haematol; 2024 Jan; 204(1):229-239. PubMed ID: 37871900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
    Bacher U; Haferlach T; Alpermann T; Zenger M; Hochhaus A; Beelen DW; Uppenkamp M; Rummel M; Kern W; Schnittger S; Haferlach C
    Br J Haematol; 2011 Mar; 152(6):713-20. PubMed ID: 21275954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
    Mullighan CG
    Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2.
    Imai K; Zhu Y; Revy P; Morio T; Mizutani S; Fischer A; Nonoyama S; Durandy A
    Clin Immunol; 2005 Jun; 115(3):277-85. PubMed ID: 15893695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies.
    Conant JL; Czuchlewski DR
    Int J Lab Hematol; 2019 May; 41 Suppl 1():126-130. PubMed ID: 31069976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.